Skip to main content

Table 3 Hematologic and serologic parameters Day -14 to end of treatment (EOT)

From: Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial

Patient # White blood cells
(× 109/l)
RR 3.9-10.7
Absolute lymphocytes
(× 109/l)
RR 0.9-4.3
Absolute neutrophils
(× 109/l)
RR 2.0-7.2
  Day
-14
Day 1 Day 14 (± 1) EOT Day
-14
Day 1 Day 14 (± 1) EOT Day
-14
Day 1 Day 14 (± 1) EOT
2 11.2 6.0 8.3 3.8 1.7 1.6 1.7 2.0 8.9 4.1 6.4 1.6L1
8 6.3 15.1 12.4 8.1 0.8L2 0.9 1.3 1.0 5.0 13.7 10.6 7.0
3 5.7 11.1 8.1 4.7 0.9 0.7L2 0.5L2 0.2L3 4.4 10.1 7.4 4.3
5 2.8L2 15.6 N/A N/A 1.0 3.4 N/A N/A 1.6L1 10.6 N/A N/A
13 14.7 5.6 8.5 7.6 1.5 0.7L2 0.5L3 0.7L2 13.1 4.7 7.8 6.5
14 15.5 a 15.2 8.3b 7.1 0.9a 1.8 0.8L1, b 0.8L1 13.7 a 12.9 7.0b 5.7
  CD4 + (cells/μl) [%]
RR 404-1612 [33-58]
Complement C3 (g/l)
RR 0.9-1.8
Anti-dsDNA (IU/ml)
< 30.0, negative; 30-75, borderline; > 75, positive
Patient # Day 1 Day 28 (± 2) EOT Day 1 Day 14 (± 1) EOT Day
-14
Day 1 Day 14 (± 1) EOT
2 489 [25.8L] 1731 [34.1] 980 [44.6] 0.686L 0.904 0.721L 917.2 375.7 168.1 463.9
8 277L2 [23.5L]c 273L2 [29.7L] 195L3 [24.0L] 0.915 1.150 1.070 325.5 306.1 97.6 20.1
3 N/A 56L3 [13.7L] 45L4 [21.4L] 0.533L 0.800L 0.906 155.3 77.6 37.5 < 12.3
5 529 [22.1L] 809 [30.1L] 603 [46.8] 1.030 1.630 1.700 56.7 43.0 34.3 12.6
13 240L2 [38.7] 95L3 [23.8L] 163L3 [19.3L] 0.462L 0.717 0.909 87.5 26.0 13.0 12.7
14 135L3 [19.1L] N/A 158L3 [19.9L] 0.434L 0.541b 0.609L 349.6 88.1 28.8b 20.1
  1. Patients #2 and #8 randomized to placebo; Patients #3, #5, #13 and #14 randomized to atacicept 150 mg subcutaneously twice weekly (4 weeks), then 150 mg weekly (48 weeks). N/A, not available; RR, reference range. Values > ULN indicated in italics; LValues < LLN, with Grade (1 to 4), where applicable. aMeasured Day -10; bMeasured Day 18; cMeasured Day 4.